GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
JPH07504184A
(ja)
|
1992-02-20 |
1995-05-11 |
ジェイムズ・ブラック・ファウンデーション・リミテッド |
コレストシストキニン抑制剤としてのビシクロ[2,2,2]オクタン誘導体
|
JPH08508743A
(ja)
|
1993-04-15 |
1996-09-17 |
グラクソ、ウェルカム、インコーポレーテッド |
Cckおよび/またはガストリン拮抗作用を有する1,5−ベンゾジアゼピン誘導体
|
KR100477070B1
(ko)
|
1994-03-25 |
2006-04-21 |
이소테크니카 인코포레이티드 |
중수소화작용에의한의약품의효능강화법
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
CA2186900A1
(en)
|
1994-04-14 |
1995-10-26 |
Christopher Joseph Aquino |
Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
|
JPH09511998A
(ja)
|
1994-04-15 |
1997-12-02 |
グラクソ、ウェルカム、インコーポレーテッド |
1,4 − ベンゾジアゼピン化合物を用いたコレシストキニンアゴニスト活性の誘導方法
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
CA2251576C
(en)
|
1996-04-12 |
2012-08-21 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
WO2002034743A1
(en)
|
2000-10-26 |
2002-05-02 |
Sanofi-Synthelabo |
Triazole derivatives and pharmaceutical compositions comprising them
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
AU2002233089B2
(en)
|
2001-02-16 |
2005-12-22 |
Conjuchem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
KR20050088283A
(ko)
*
|
2002-10-30 |
2005-09-05 |
버텍스 파마슈티칼스 인코포레이티드 |
Rock 및 기타 단백질 키나제의 억제제로서 유용한조성물
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
WO2005095338A1
(ja)
|
2004-03-30 |
2005-10-13 |
Takeda Pharmaceutical Company Limited |
アルコキシフェニルプロパン酸誘導体
|
JP4069159B2
(ja)
|
2004-05-25 |
2008-04-02 |
ファイザー・プロダクツ・インク |
テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
AU2006211514A1
(en)
|
2005-01-28 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
WO2006083781A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
KR101200227B1
(ko)
|
2005-05-04 |
2012-11-13 |
질랜드 파마 에이/에스 |
글루카곤 유사 펩티드-2(glp-2) 유사체
|
KR100962732B1
(ko)
|
2005-06-02 |
2010-06-09 |
에프. 호프만-라 로슈 아게 |
피페리딘-4-일-아마이드 유도체 및 sst 수용체 아형 5길항제로서 그의 용도
|
CA2627444A1
(en)
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
WO2007088857A1
(ja)
|
2006-01-31 |
2007-08-09 |
Takeda Pharmaceutical Company Limited |
遺伝子改変動物およびその用途
|
DE602007008868D1
(de)
|
2006-04-14 |
2010-10-14 |
Merck Sharp & Dohme |
Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
|
MX2008013237A
(es)
|
2006-04-14 |
2009-03-06 |
Merck & Co Inc |
Imidazol 4-caroxamidas sustituidas como moduladores del receptor colecistoquinina-1.
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
JP5271895B2
(ja)
|
2006-05-15 |
2013-08-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗糖尿病性の二環式化合物
|
WO2008028117A2
(en)
|
2006-08-31 |
2008-03-06 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
WO2008063768A2
(en)
|
2006-10-12 |
2008-05-29 |
Case Western Reserve University |
Compositions and methods for treating metabolic diseases
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
CA2667249A1
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
JP5819586B2
(ja)
|
2006-11-08 |
2015-11-24 |
ジーランド ファーマ アクティーゼルスカブ |
選択的グルカゴン様ペプチド−2(glp−2)類似体
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
AU2007325315A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys Inc |
Heterocyclic modulators of TGR5
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
MX2009007728A
(es)
|
2007-01-19 |
2009-12-15 |
Intercept Pharmaceuticals Inc |
Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos.
|
JP2010516768A
(ja)
|
2007-01-26 |
2010-05-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
コレシストキニン−1レセプターモジュレーターとしての置換アミノピリミジン
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
US20100286112A1
(en)
|
2007-09-10 |
2010-11-11 |
Oscar Barba |
Compounds for the treatment of metabolic disorders
|
CN101801954B
(zh)
|
2007-09-20 |
2013-10-09 |
Irm责任有限公司 |
作为gpr119活性调节剂的化合物和组合物
|
EP2203415B1
(de)
|
2007-09-21 |
2016-10-26 |
Sanofi |
(cyclopropyl-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
CA2700028A1
(en)
|
2007-09-21 |
2009-04-02 |
Sanofi-Aventis |
(carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
|
EP2216340B1
(en)
|
2007-10-17 |
2012-12-12 |
Universidad De Córdoba |
Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligonucleotide pairs for detection thereof by pcr
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
WO2009054468A1
(ja)
|
2007-10-24 |
2009-04-30 |
Astellas Pharma Inc. |
アゾールカルボキサミド化合物又はその塩
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
NZ584161A
(en)
|
2007-10-26 |
2011-12-22 |
Japan Tobacco Inc |
Spiro-ring compound and use thereof for medical purposes
|
US8399507B2
(en)
|
2007-10-29 |
2013-03-19 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックIpマネジメント株式会社 |
発光装置および照明器具
|
WO2009126535A1
(en)
|
2008-04-07 |
2009-10-15 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
WO2010014836A2
(en)
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
US20110171164A1
(en)
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
AU2009314200B2
(en)
|
2008-11-17 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
ES2592452T3
(es)
|
2008-11-19 |
2016-11-30 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y métodos de uso de los mismos
|
KR101789960B1
(ko)
|
2008-11-19 |
2017-10-25 |
인터셉트 파마슈티컬즈, 인크. |
Tgr5 조절제 및 그의 사용 방법
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
EP2389369A1
(en)
|
2009-01-23 |
2011-11-30 |
Schering Corporation |
Pentafluorosulpholane-containing antidiabetic compounds
|
AU2010206789A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Bridged and fused antidiabetic compounds
|
WO2010091176A1
(en)
|
2009-02-05 |
2010-08-12 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
KR20110119790A
(ko)
|
2009-02-12 |
2011-11-02 |
엑셀리시스, 인코포레이티드 |
당뇨병 및 비만을 치료하는데 tgr5 효능제로서 사용되는 트리아졸 및 이미다졸 유도체
|
JP5657518B2
(ja)
|
2009-02-18 |
2015-01-21 |
武田薬品工業株式会社 |
縮合複素環化合物
|
RU2011147232A
(ru)
|
2009-04-22 |
2013-05-27 |
Астеллас Фарма Инк. |
Производное карбоновой кислоты
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
US20120172351A1
(en)
|
2009-06-09 |
2012-07-05 |
Nobuyuki Negoro |
Novel fused cyclic compound and use thereof
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
JPWO2011052756A1
(ja)
|
2009-10-30 |
2013-03-21 |
持田製薬株式会社 |
新規3−ヒドロキシ−5−アリールイソキサゾール誘導体
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
US8846739B2
(en)
|
2009-12-11 |
2014-09-30 |
Exelixis Patent Company Llc |
TGR5 agonists
|
NZ601408A
(en)
|
2009-12-25 |
2013-12-20 |
Mochida Pharm Co Ltd |
Novel 3-hydroxy-5-arylisothiazole derivative
|
EP2571356A4
(en)
|
2010-05-18 |
2013-11-20 |
Merck Sharp & Dohme |
SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
AU2011281134B2
(en)
|
2010-07-23 |
2015-05-14 |
Connexios Life Sciences Pvt. Ltd. |
Agonists of GPR40
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
CA2846680C
(en)
|
2010-08-30 |
2019-06-25 |
Takeda Gmbh |
Solid phase synthesis of h[gly2]glp-2
|
WO2012046869A1
(ja)
|
2010-10-08 |
2012-04-12 |
持田製薬株式会社 |
環状アミド誘導体
|
WO2012070554A1
(ja)
|
2010-11-22 |
2012-05-31 |
国立大学法人京都大学 |
ペプチド
|
PL2646425T3
(pl)
|
2010-12-01 |
2015-12-31 |
Boehringer Ingelheim Int |
Kwasy indanyloksydihydrobenzofuranylooctowe użyteczne do leczenia zespołu metabolicznego
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
AR085252A1
(es)
|
2011-02-17 |
2013-09-18 |
Takeda Pharmaceutical |
Metodo de produccion de derivado de dihidrobenzofurano opticamente activo
|
JP5977814B2
(ja)
|
2011-04-08 |
2016-08-24 |
アムジエン・インコーポレーテツド |
増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
|
EP2693882B1
(en)
*
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
JP5420796B2
(ja)
|
2011-04-27 |
2014-02-19 |
持田製薬株式会社 |
新規3−ヒドロキシイソチアゾール1−オキシド誘導体
|
US9062028B2
(en)
|
2011-04-28 |
2015-06-23 |
Bristol-Myers Squibb Company |
Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
|
EP2720544B1
(en)
*
|
2011-06-16 |
2016-12-21 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
AR087451A1
(es)
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
JP6206972B2
(ja)
|
2011-09-12 |
2017-10-04 |
アムニクス オペレーティング インコーポレイテッド |
グルカゴン様ペプチド−2組成物およびその作製法および使用法
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
CA2855009C
(en)
*
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
AU2012358359A1
(en)
|
2011-12-21 |
2014-07-24 |
Ardelyx, Inc. |
Non-systemic TGR5 agonists
|
AU2012365706B2
(en)
|
2012-01-12 |
2015-08-20 |
Jiangsu Hengrui Medicine Co., Ltd. |
Polycyclic derivatives, preparation method and medical uses thereof
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
WO2013122028A1
(ja)
|
2012-02-13 |
2013-08-22 |
武田薬品工業株式会社 |
芳香環化合物
|
US9181186B2
(en)
|
2012-02-13 |
2015-11-10 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
AU2013227266A1
(en)
|
2012-02-28 |
2014-10-02 |
Piramal Enterprises Limited |
Phenyl alkanoic acid derivatives as GPR agonists
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
AU2013255752B2
(en)
|
2012-05-03 |
2017-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US20150274664A1
(en)
*
|
2012-09-26 |
2015-10-01 |
Marck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
MX361653B
(es)
|
2012-10-26 |
2018-12-13 |
Intercept Pharmaceuticals Inc |
Procedimiento para la preparación de derivados del ácido biliar.
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
AP2015008364A0
(en)
|
2012-11-28 |
2015-04-30 |
Boehringer Ingelheim Int |
New idanyloxydihydrobenzof uranylacetic acids
|
EP2925328A1
(en)
|
2012-11-28 |
2015-10-07 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
EP2953681B1
(en)
|
2013-02-06 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
New indanyloxydihydrobenzofuranylacetic acids
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
AR096041A1
(es)
|
2013-04-17 |
2015-12-02 |
Piramal Entpr Ltd |
Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
|
WO2014187343A1
(zh)
|
2013-05-22 |
2014-11-27 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
CN105636984A
(zh)
|
2013-06-13 |
2016-06-01 |
法斯特弗沃德制药有限公司 |
用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物,该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
NZ754961A
(en)
|
2013-07-31 |
2022-04-29 |
Amgen Inc |
Growth differentiation factor 15 (gdf-15) constructs
|
LT3031799T
(lt)
|
2013-08-09 |
2018-06-25 |
Takeda Pharmaceutical Company Limited |
Aromatinis junginys
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
US20160200734A1
(en)
|
2013-08-23 |
2016-07-14 |
Xinshan Kang |
Carboxylic acid compounds in treatment of diabetes mellitus
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
EP3049396B1
(en)
|
2013-09-26 |
2017-11-15 |
Boehringer Ingelheim International GmbH |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
CN105722841A
(zh)
|
2013-11-14 |
2016-06-29 |
卡迪拉保健有限公司 |
新型杂环化合物
|
ES2747973T3
(es)
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
WO2015105779A1
(en)
|
2014-01-10 |
2015-07-16 |
Eli Lilly And Company |
Isopropyl triazolo pyridine compounds
|
BR112016013874A2
(pt)
|
2014-01-10 |
2017-08-08 |
Lilly Co Eli |
Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
|
EP3102198B1
(en)
|
2014-02-06 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
PL3626725T3
(pl)
|
2014-05-29 |
2023-04-03 |
Bar Pharmaceuticals S.R.L. |
Pochodne cholanu do zastosowania w leczeniu i/lub zapobieganiu chorobom, w których pośredniczy fxr i tgr5/gpbar1
|
WO2015198199A1
(en)
|
2014-06-23 |
2015-12-30 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof.
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
WO2016066818A1
(en)
|
2014-10-31 |
2016-05-06 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
RU2017118569A
(ru)
|
2014-11-06 |
2018-12-06 |
Энанта Фармасьютикалс, Инк. |
Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
SG11201706089RA
(en)
|
2015-02-11 |
2017-09-28 |
Enanta Pharm Inc |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
CN107427527B
(zh)
|
2015-03-31 |
2021-01-26 |
英安塔制药有限公司 |
作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
CA2989167A1
(en)
|
2015-06-19 |
2016-12-22 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
JP6772133B2
(ja)
|
2015-07-02 |
2020-10-21 |
サントリーホールディングス株式会社 |
Glp−2分泌促進用組成物
|
WO2017005765A1
(en)
|
2015-07-06 |
2017-01-12 |
Novo Nordisk A/S |
Novel peptides and peptide derivatives and uses thereof
|
MX2018001491A
(es)
|
2015-08-07 |
2018-04-24 |
Intercept Pharmaceuticals Inc |
Metodos para la preparacion de acidos biliares y derivados de los mismos.
|
EP3331860B1
(en)
|
2015-08-07 |
2019-07-17 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
EP3347358B1
(en)
|
2015-09-09 |
2019-11-27 |
Boehringer Ingelheim International GmbH |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
US11072631B2
(en)
|
2015-09-24 |
2021-07-27 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation bile acid derivatives
|
JP6749406B2
(ja)
|
2015-11-06 |
2020-09-02 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
オベチコール酸およびその誘導体の調製方法
|
TW202246215A
(zh)
|
2015-12-18 |
2022-12-01 |
美商亞德利克斯公司 |
作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
EP3423094A4
(en)
|
2016-02-29 |
2019-11-06 |
Eli Lilly and Company |
GFRAL RECEPTOR THERAPIES
|
EP3436003B1
(en)
|
2016-03-29 |
2023-08-23 |
Merck Sharp & Dohme LLC |
Antidiabetic bicyclic compounds
|
WO2017180571A1
(en)
|
2016-04-11 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
|
JP6968821B2
(ja)
|
2016-04-13 |
2021-11-17 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
癌を治療する方法
|
US10654834B2
(en)
|
2016-07-01 |
2020-05-19 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
WO2018005801A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
WO2018064441A1
(en)
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc |
Crystalline forms of a bile acid derivative
|
CA3038846A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
US10538490B2
(en)
|
2016-10-25 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
EP3544958B1
(en)
|
2016-11-28 |
2021-03-24 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
AU2017371516C1
(en)
|
2016-12-09 |
2021-09-02 |
Zealand Pharma A/S |
Acylated GLP-1/GLP-2 dual agonists
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
JP2020500890A
(ja)
|
2016-12-09 |
2020-01-16 |
ジーランド・ファーマ・ア/エス |
Glp−1/glp−2二重アゴニスト
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
JP7050792B2
(ja)
|
2017-01-26 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
US10913720B2
(en)
|
2017-01-26 |
2021-02-09 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
JP6968181B2
(ja)
|
2017-01-26 |
2021-11-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
JP7049349B2
(ja)
|
2017-01-26 |
2022-04-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
US10919859B2
(en)
|
2017-01-26 |
2021-02-16 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
WO2018146008A1
(en)
|
2017-02-08 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
CN110719903A
(zh)
|
2017-03-31 |
2020-01-21 |
武田药品工业株式会社 |
芳族环化合物
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
EP3638291B1
(en)
|
2017-06-16 |
2021-08-18 |
Zealand Pharma A/S |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
AU2018288883B2
(en)
|
2017-06-23 |
2022-06-02 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation of bile acid derivatives
|
US20200199192A1
(en)
|
2017-08-22 |
2020-06-25 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
MX2020004620A
(es)
|
2017-11-06 |
2020-10-12 |
Shire Nps Pharmaceuticals Inc |
Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.
|
US11225471B2
(en)
|
2017-11-16 |
2022-01-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
DK3737470T5
(da)
|
2018-01-08 |
2024-05-27 |
Celon Pharma Sa |
3-phenyl-4-hexynsyrederivater som gpr40-agonister
|
WO2020197926A1
(en)
|
2019-03-22 |
2020-10-01 |
Kallyope, Inc. |
Gpcr combination therapies
|
US20220226298A1
(en)
|
2019-05-29 |
2022-07-21 |
Kallyope, Inc. |
Gpr40 agonists
|
BR112022006546A2
(pt)
|
2019-10-07 |
2022-08-30 |
Kallyope Inc |
Agonistas de gpr119
|
WO2021113362A1
(en)
|
2019-12-03 |
2021-06-10 |
Kallyope, Inc. |
Sstr5 antagonists
|
WO2021174048A1
(en)
|
2020-02-28 |
2021-09-02 |
Kallyope, Inc. |
Gpr40 agonists
|
JP2023528713A
(ja)
|
2020-02-28 |
2023-07-06 |
キャリーオペ,インク. |
Gpr40アゴニスト
|